Protein-Based Therapeutics - Page 2 of 8 - EpiVax, Inc. - Informatics and Immunology

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

by Annie De Groot | Jun 30, 2020

2020 TCWP

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

by Annie De Groot | Sep 9, 2019

EpiVax_PANDA_Taspoglutide_April_19_Final

Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics

Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics

by Sarah Moniz | Aug 15, 2018

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

by Sarah Moniz | Aug 15, 2018

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

by Sarah Moniz | Apr 10, 2018

« Older Entries

Next Entries »